Sector News

Roche buys U.S.-based Kapa Biosystems

August 20, 2015
Life sciences
(MarketWatch) – Roche Holding AG (ROG.VX) Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company.
 
Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum. The closely held U.S. company has been working on ways to accelerate research into genomes, the complete set of DNA with within a single cell.
 
Roche is interested in the area because it leads to a better understanding of the genetic roots of diseases by identifying genetic mutations. Genome research can affect the future ability to diagnose, monitor and treat cancer and other conditions.
 
Kapa’s protein-engineering technology allows for the generation and screening of large numbers of enzyme variants, Roche said. Tailored enzymes with improved performance for specific applications can be rapidly selected, speeding up product development time lines, the company added.
 
Last week, Roche said it was buying GeneWEAVE BioSciences, a California-based developer of clinical microbiology with diagnostics solutions, for an initial $190 million.
 

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend